Abstract

Peripheral T-cell lymphoma (PTCL) is a heterogeneous group of non-Hodgkin lymphomas with poor prognosis. Up to 30% of PTCL lack distinctive features and are classified as PTCL, not otherwise specified (PTCL-NOS). To further improve our understanding of the genetic landscape and biology of PTCL-NOS, we perform RNA-sequencing of 18 cases and validate results in an independent cohort of 37 PTCL cases. We identify FYN-TRAF3IP2, KHDRBS1-LCK and SIN3A-FOXO1 as new in-frame fusion transcripts, with FYN-TRAF3IP2 as a recurrent fusion detected in 8 of 55 cases. Using ex vivo and in vivo experiments, we demonstrate that FYN-TRAF3IP2 and KHDRBS1-LCK activate signaling pathways downstream of the T cell receptor (TCR) complex and confer therapeutic vulnerability to clinically available drugs.

Peripheral T cell lymphoma (PTCL) not otherwise specified (NOS) is a subgroup of PTCL, which has no distinctive features and is poorly characterized at the genetic level. Here, the authors identify two fusion transcripts that activate T cell receptor complex signalling and confer therapeutic vulnerability in PTCL-NOS.

Details

Title
Fusion transcripts FYN-TRAF3IP2 and KHDRBS1-LCK hijack T cell receptor signaling in peripheral T-cell lymphoma, not otherwise specified
Author
Debackere Koen 1 ; Marcelis Lukas 2 ; Demeyer Sofie 3 ; Vanden Bempt Marlies 4   VIAFID ORCID Logo  ; Mentens Nicole 3 ; Gielen, Olga 3   VIAFID ORCID Logo  ; Jacobs, Kris 3 ; Broux, Michael 3 ; Verhoef, Gregor 5 ; Michaux Lucienne 6 ; Graux Carlos 7 ; Wlodarska Iwona 6 ; Gaulard Philippe 8 ; de Leval Laurence 9   VIAFID ORCID Logo  ; Tousseyn, Thomas 10 ; Cools, Jan 3   VIAFID ORCID Logo  ; Dierickx Daan 5   VIAFID ORCID Logo 

 Laboratory for Experimental Hematology, KU Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040) 
 Translational Cell & Tissue Research, KU Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884) 
 Center for Cancer Biology, VIB, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Center for Human Genetics, KU Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884) 
 Laboratory for Experimental Hematology, KU Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Cancer Biology, VIB, Leuven, Belgium (GRID:grid.11486.3a) (ISNI:0000000104788040); Center for Human Genetics, KU Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884) 
 Laboratory for Experimental Hematology, KU Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); University Hospitals Leuven, Department of Hematology, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338) 
 Center for Human Genetics, KU Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); Center for Human Genetics, University Hospitals Leuven, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338) 
 Mont-Godinne University Hospital, Yvoir, Belgium (GRID:grid.411754.2) 
 Département de Pathologie, Groupe Hospitalier Henri Mondor, AP-HP, Créteil, France (GRID:grid.411388.7) (ISNI:0000 0004 1799 3934); INSERM U955 and Université Paris-Est, Créteil, France (GRID:grid.411388.7) 
 Institute of Pathology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and Lausanne University, Lausanne, Switzerland (GRID:grid.9851.5) (ISNI:0000 0001 2165 4204) 
10  Translational Cell & Tissue Research, KU Leuven, Leuven, Belgium (GRID:grid.5596.f) (ISNI:0000 0001 0668 7884); University Hospitals Leuven, Department of Pathology, Leuven, Belgium (GRID:grid.410569.f) (ISNI:0000 0004 0626 3338) 
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2542128322
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.